Endometrial cancer: Potential treatment and prevention with progestin-containing intrauterine devices

Obstetrics and Gynecology

Volumn 119, Issue 2 PART 2, 2012, Pages 419-420

  Leslie, Kimberly K ^a   Thiel, Kristina W ^a   Yang, Shujie ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; PROGESTERONE RECEPTOR; CONTRACEPTIVE AGENT; LEVONORGESTREL;

CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGRESSION; DISEASE ASSOCIATION; EDITORIAL; ENDOMETRIUM CANCER; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MORBID OBESITY; NULLIPARA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; ADENOCARCINOMA; ENDOMETRIUM TUMOR; FEMALE; NOTE;

ADENOCARCINOMA; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL;

EID: 84858762764     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182444f15     Document Type: Editorial

References (6)

1. American Cancer Society. Cancer facts and figures 2011. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-029771.pdf. Retrieved November 21, 2011.
2. Brown AJ, Westin SN, Broaddus RR, Schmeler K. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol 2012;119:423-6.
3. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab 2011;22:145-52.
4. Yang S, Thiel KW, De Geest K, Leslie KK. Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med 2011;12:205-12.
5. Chang SC, Lacey JV Jr, Brinton LA, Hartge P, Adams K, Mouw T, et al. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2007;16:723-30. (Pubitemid 46650574)
6. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010;2010:162363.